Vermillion Announces U.S. Patent Office Re-Issues Seldi Mass Spectrometry Patent
News Nov 07, 2007
Vermillion, Inc. has announced that the United States Patent and Trademark Office has issued a Reexamination Certificate of U.S. Patent No. 6,734,022, which is directed to a fundamental process of SELDI mass spectrometry.
As a result of the patent reissuance, Bio-Rad Laboratories is expected to pay Vermillion $2.0 million pursuant to the terms of the Asset Purchase Agreement entered into in connection with the sale of Vermillion's instrumentation business to Bio-Rad on November 13, 2006.
"We believe this patent further validates the innovation underlying SELDI technology and look forward to receiving Bio-Rad's payment," said Gail S. Page, President and Chief Executive Officer of Vermillion. "We continue to make excellent progress translating the SELDI-enabled biomarker discoveries into novel, high-value molecular diagnostic tests."
High-Resolution Mass Spectrometry Reveals Pathways in Photosystem II Water SystemNews
Researchers have capitalised on the incredible accuracy, speed and sensitivity of new mass spectrometry instruments to provide the first comprehensive study of how an ancient photosynthetic organism uses and regulates water to create energy.READ MORE
SCIEX Announces Joint Venture with Zhenjang Dian Diagnostics in ChinaNews
Leading diagnostics companies combine to address diagnostic and wellness testing in China.READ MORE
Long-Lasting Issues from Inflexible ClogsNews
Researchers used osteobiography and paleopathology methods as well as stable isotope analysis and mass spectrometry on a group of skeletons, to analyse diet, disease and overall health. This revealed wooden clogs were likely to blame for injuries to the individual's feet.READ MORE